ES2927888T3 - Análogos de pridopidina, su preparación y uso - Google Patents

Análogos de pridopidina, su preparación y uso Download PDF

Info

Publication number
ES2927888T3
ES2927888T3 ES15814023T ES15814023T ES2927888T3 ES 2927888 T3 ES2927888 T3 ES 2927888T3 ES 15814023 T ES15814023 T ES 15814023T ES 15814023 T ES15814023 T ES 15814023T ES 2927888 T3 ES2927888 T3 ES 2927888T3
Authority
ES
Spain
Prior art keywords
pridopidine
compound
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15814023T
Other languages
English (en)
Spanish (es)
Inventor
Malle Schmidt
Malle Päri
Marit Laos
Ants Maasalu
Kalle Kaljuste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Application granted granted Critical
Publication of ES2927888T3 publication Critical patent/ES2927888T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Spectroscopy & Molecular Physics (AREA)
ES15814023T 2014-06-30 2015-06-29 Análogos de pridopidina, su preparación y uso Active ES2927888T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462019337P 2014-06-30 2014-06-30
US201462076436P 2014-11-06 2014-11-06
PCT/US2015/038349 WO2016003919A1 (en) 2014-06-30 2015-06-29 Analogs of pridopidine, their preparation and use

Publications (1)

Publication Number Publication Date
ES2927888T3 true ES2927888T3 (es) 2022-11-11

Family

ID=54929343

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15814023T Active ES2927888T3 (es) 2014-06-30 2015-06-29 Análogos de pridopidina, su preparación y uso

Country Status (17)

Country Link
US (4) US10130621B2 (cg-RX-API-DMAC7.html)
EP (2) EP4049998A1 (cg-RX-API-DMAC7.html)
JP (2) JP6800842B2 (cg-RX-API-DMAC7.html)
CN (2) CN113511997A (cg-RX-API-DMAC7.html)
AU (1) AU2015284385B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016030968B1 (cg-RX-API-DMAC7.html)
CA (1) CA2951494C (cg-RX-API-DMAC7.html)
DK (1) DK3160470T3 (cg-RX-API-DMAC7.html)
EA (1) EA201790101A1 (cg-RX-API-DMAC7.html)
ES (1) ES2927888T3 (cg-RX-API-DMAC7.html)
HU (1) HUE060242T2 (cg-RX-API-DMAC7.html)
IL (2) IL249601B (cg-RX-API-DMAC7.html)
MX (1) MX382649B (cg-RX-API-DMAC7.html)
PL (1) PL3160470T3 (cg-RX-API-DMAC7.html)
TW (1) TW201613859A (cg-RX-API-DMAC7.html)
UY (1) UY36192A (cg-RX-API-DMAC7.html)
WO (1) WO2016003919A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
SMT202600016T1 (it) * 2019-06-12 2026-03-09 Prilenia Neurotherapeutics Ltd Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi
EP4741013A3 (en) * 2020-02-13 2026-08-05 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral sclerosis using pridopidine and another active agent
JP7603713B2 (ja) * 2020-05-04 2024-12-20 プリレニア ニューロセラピューティクス リミテッド 選択的s1rアゴニストを使用するウイルス感染、疾患、又は障害の治療
AU2021366505A1 (en) * 2020-10-20 2023-06-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine and analogs for the treatment of anxiety and depression
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
CA3214354A1 (en) * 2021-04-14 2022-10-20 Michael Hayden Treatment of prodromal huntington disease
WO2023062632A1 (en) * 2021-10-11 2023-04-20 Prilenia Neurotherapeutics Ltd. Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
CN114716391B (zh) * 2022-04-24 2023-12-12 杭州仟源保灵药业有限公司 一种醋甲唑胺杂质及其制备方法和应用
CA3250337A1 (en) 2022-05-03 2023-11-09 Prilenia Neurotherapeutics Ltd. METHODS AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE
CN118924710B (zh) * 2024-08-05 2026-06-19 成都新睿志远生物医药股份有限公司 细辛脑在制备治疗和/或预防眼部疾病药物中的应用和一种组合物及其应用
WO2026035949A1 (en) * 2024-08-08 2026-02-12 Prilenia Therapeutics Inc. Combination of pridopidine and low dose anti-dopaminergic medication (adm) for treating huntington disease and sympto thereof
WO2026080658A1 (en) 2024-10-10 2026-04-16 Prilenia Therapeutics Inc. Pridopidine for the treatment of distal hereditary motor neuropathy (dhmn)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6472736A (en) 1987-09-14 1989-03-17 Toshiba Corp Mri apparatus
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
JP2008501748A (ja) * 2004-06-08 2008-01-24 ニューロサーチ スウェーデン アクチボラゲット ドーパミン神経伝達のモジュレーターとしての新規な置換されたピペリジン
US7629461B2 (en) * 2004-09-04 2009-12-08 Teva Pharmaceutical Industries Ltd Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
ES2659577T3 (es) * 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
MX2007004216A (es) * 2004-10-13 2007-10-10 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-sulfonil)-piperidinas.
JP2007526342A (ja) * 2005-01-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 低レベルの不純物を有するオルメサルタンメドキソミル
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
MX2009011020A (es) * 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
US20100197712A1 (en) 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US20150209346A1 (en) * 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003812A (es) 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
IL311081A (en) * 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline

Also Published As

Publication number Publication date
DK3160470T3 (da) 2022-10-24
CN113511997A (zh) 2021-10-19
US11141412B2 (en) 2021-10-12
US10406145B2 (en) 2019-09-10
AU2015284385B2 (en) 2021-01-21
US20220023280A1 (en) 2022-01-27
PL3160470T3 (pl) 2022-11-21
EP3160470A4 (en) 2018-01-10
CA2951494C (en) 2023-10-03
US20190030016A1 (en) 2019-01-31
US20150374677A1 (en) 2015-12-31
IL272306B (en) 2021-04-29
IL249601A0 (en) 2017-02-28
US10130621B2 (en) 2018-11-20
EP3160470B1 (en) 2022-08-03
CN106456618A (zh) 2017-02-22
EA201790101A1 (ru) 2017-06-30
WO2016003919A1 (en) 2016-01-07
HK1231406A1 (en) 2017-12-22
WO2016003919A8 (en) 2017-01-26
BR112016030968A2 (pt) 2018-07-17
EP4049998A1 (en) 2022-08-31
MX382649B (es) 2025-03-13
UY36192A (es) 2016-01-29
BR112016030968B1 (pt) 2023-11-21
JP7035108B2 (ja) 2022-03-14
JP2020143072A (ja) 2020-09-10
AU2015284385A1 (en) 2017-02-02
IL249601B (en) 2020-01-30
JP6800842B2 (ja) 2020-12-16
MX2016017332A (es) 2017-05-12
IL272306A (en) 2020-03-31
JP2017519839A (ja) 2017-07-20
TW201613859A (en) 2016-04-16
US20200030308A1 (en) 2020-01-30
HUE060242T2 (hu) 2023-02-28
EP3160470A1 (en) 2017-05-03
CA2951494A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
EP3160470B1 (en) Analogs of pridopidine, their preparation and use
EP3317281B1 (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
ES3028360T3 (en) Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
JP5399926B2 (ja) 血管阻害物質とタキサンとの併用
ES2600920T3 (es) Preparaciones estables de laquinimod
AU2019277372B2 (en) Pharmaceutically acceptable salts of sepiapterin
US20150258105A1 (en) Methods for acute and long-term treatment of alcohol dependence
ES2760373T3 (es) Compuestos y procedimientos para prevenir o tratar la muerte de células ciliadas sensoriales
US20150342959A1 (en) Methods and compositions for sustained noribogaine treatment
ES3044409T3 (en) Salts and crystalline forms of a taar1 agonist
US11254700B2 (en) GSK-3β inhibitors and use thereof in methods of treatment
HK40078313A (en) Analogs of pridopidine, their preparation and use
HK1231406B (en) Analogs of pridopidine, their preparation and use
HK1233503A1 (en) Analogs of pridopidine, their preparation and use
EA041145B1 (ru) Фармацевтические композиции, содержащие производные придопидина, их применение для лечения пациента, страдающего нейродегенеративным заболеванием или нейродегенеративным расстройством
HK40099362A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
HK40070770A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
WO2023133354A2 (en) Development of potential antidotes for arsenicals
BR112020003865B1 (pt) Composições farmacêuticas compreendendo sepiapterina e usos das mesmas
HK1250511B (en) Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide